New hope for colon cancer: ctDNA-Guided treatment aims to prevent relapse
NCT ID NCT05062889
First seen Feb 03, 2026 · Last updated May 25, 2026 · Updated 14 times
Summary
This study is for people with stage II or III colon cancer who are at high risk of the cancer coming back after surgery. Researchers are testing whether stronger chemotherapy (FOLFOXIRI) followed by an extra drug (Trifluridine/Tipiracil) can make cancer DNA in the blood disappear, which may lower the chance of relapse. The study also includes a special group for patients with HER2-positive cancer who will receive targeted therapy. The goal is to see if these treatments improve outcomes without causing too many side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O.U Careggi
Florence, 50134, Italy
-
A.O.U. di Ferrara Arcispedale Sant'Anna
Ferrara, 44100, Italy
-
AOU Cagliari PO Policlinico Universitario Duilio Casula Presidio Policlinico Universitario "Duilio Casula"
Cagliari, 09042, Italy
-
AUSL Romagna
Ravenna, 48121, Italy
-
Azienda Ospedaliera Cardinale Giovanni Panico
Tricase, Lecce, 73039, Italy
-
Azienda Ospedaliero Universitaria Maggiore della Carita
Novara, 28100, Italy
-
Azienda Sanitaria Universitaria Friuli Centrale
Udine, 33100, Italy
-
Azienda USL IRCCS di Reggio Emilia (centro principale Reggio Emilia e centro satellite Guastalla).
Reggio Emilia, 42123, Italy
-
Azienda USL Toscana Nord Ovest di Livorno
Livorno, 57124, Italy
-
Azienda USL di Piacenza
Piacenza, 29121, Italy
-
E.O. Ospedali Galliera di Genova
Genova, 16128, Italy
-
Fondazione Casa Sollievo della Sofferenza
San Giovanni Rotondo, Foggia, 71013, Italy
-
Fondazione IRCCS INT - Milano
Milan, 20133, Italy
-
Fondazione POLIAMBULANZA ISTITUTO OSPEDALIERO
Brescia, 25124, Italy
-
IRCCS di Candiolo
Torino, 10060, Italy
-
Istituto Oncologico Veneto IOV - IRCCS
Padua, 35128, Italy
-
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Meldola, 47014, Italy
-
Istituto per la ricerca sui tumori Regina Elena
Roma, 00144, Italy
-
Nuovo Ospedale di Prato
Prato, 59100, Italy
-
Ospedale Campostaggia Poggiponsi
Siena, 53100, Italy
-
Ospedale Fatebenefratelli Isola Tiberina
Roma, 00186, Italy
-
Ospedale Misericordia di Grosseto
Grosseto, 58100, Italy
-
Ospedale San Donato di Arezzo
Arezzo, 52100, Italy
-
Ospedale San Luca di Lucca
Lucca, 55100, Italy
-
Ospedale San Raffaele
Milan, 20132, Italy
-
Policlinico Fondazione Agostino Gemelli
Roma, 00168, Italy
-
Policlinico Tor Vergata Roma
Roma, 00133, Italy
-
Spedali Civili di Brescia
Brescia, 25123, Italy
Conditions
Explore the condition pages connected to this study.